Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

5%

Beneficial ownership of this reported class.

Shares

4,276,578 shares

Shares beneficially owned as disclosed.

Event date

30 Sep 2026

Date tied to the ownership event or amendment.

Accepted by SEC

16 Nov 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
GLUE
Shares outstanding
85,531,560 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
16 Nov 2026, 16:16:31 UTC
Event date
30 Sep 2026
Prior SEC filing
15 May 2026
Source filing
View source filing
Filing notes and source

Key filing fact

BIOTECHNOLOGY VALUE FUND L P disclosed 5% ownership in Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE) on 30 Sep 2026.

Key facts

  • BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A for Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE).
  • Disclosed ownership: 5%.
  • Date of event: 30 Sep 2026.

Change

  • Disclosed shares changed by -809,308 since the prior disclosure.
  • Previous schedule filing date: 15 May 2026.
  • Current filing was accepted on 16 Nov 2026, 16:16.
  • Disclosed stake changed by -1.30 percentage points.
  • Changes between disclosures can reflect transactions, share-count changes or reporting changes; they do not establish a purchase or activist intent.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (10)

Names, ownership percentages, voting power, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power CIK
BIOTECHNOLOGY VALUE FUND L P 2.6% 2,243,481 0 2,243,481
BVF I GP LLC 2.6% 2,243,481 0 2,243,481
BIOTECHNOLOGY VALUE FUND II LP 2% 1,681,945 0 1,681,945
BVF II GP LLC 2% 1,681,945 0 1,681,945
Biotechnology Value Trading Fund OS LP 0.3% 283,767 0 283,767
BVF Partners OS Ltd. 0.3% 283,767 0 283,767
BVF GP HOLDINGS LLC 4.6% 3,925,426 0 3,925,426
BVF PARTNERS L P/IL 5% 4,276,578 0 4,276,578
BVF INC/IL 5% 4,276,578 0 4,276,578
LAMPERT MARK N 5% 4,276,578 0 4,276,578
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .